Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IST:ONCSM's EV-to-OCF is ranked worse than 96.01% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.75
vs IST:ONCSM: 144.43
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio (TTM) for today is calculated as:
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's share price for today is ₺252.75.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺1.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-OCF Related Terms
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-OCF Chart
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-OCF vs Medical Devices & Instruments Industry
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Enterprise Value is ₺6,128.4 Mil.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺42.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a EV-to-OCF of 144.43 as of Jul. 27, 2026. This is 232% above median its historical median of 43.51. According to the industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #818 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 96%.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EV-to-OCF too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current EV-to-OCF of 144.43 is 232% above median its 10-year median of 43.51. The Medical Devices & Instruments industry median EV-to-OCF is 7.75. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 144.43 is 1763.6% above this industry median. Based on the distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #818 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #818 out of 852 companies for EV-to-OCF. This places Oncosem Onkolojik Sistemlernayi ve Ticaret AS in the lower half of its industry. The industry median EV-to-OCF is 7.75. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 144.43 is 1763.6% above this benchmark. While the company's 10-year median is 43.51 vs. the industry median of 7.75, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.75, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current EV-to-OCF of 144.43 is 1763.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current EV-to-OCF is 144.43, which is 232% above median its own 10-year median of 43.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺256.15, compared to a current price of ₺252.75 — trading 1.3% below its estimated fair value. The current EV-to-OCF is 144.43, which is 232% above median its 10-year median of 43.51 and 1763.6% above the Medical Devices & Instruments industry median of 7.75. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current EV-to-OCF is 144.43 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be undervalued.
The current stock price of ₺252.75 is trading 1.3% below its estimated GF Value™ of ₺256.15.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.
Key valuation signals for IST:ONCSM:
EV-to-OCF: 144.43 (232% above median its 10-year median of 43.51)
GF Value™: ₺256.15 vs. price of ₺252.75 (1.3% below fair value)
Industry Position: 1763.6% above the Medical Devices & Instruments median (#818 of 852)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
